KIYATEC Stock

KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies.

Sign up today and learn more about KIYATEC Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About KIYATEC Stock

KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies. Its 3DKUBE technology platform conveniently and cost-effectively incorporates perfusion flow, accommodates all scaffold materials, allows in situ imaging, models complex human biology using segregated cell co‐culture, and is a single-use disposable. 3DKUBE cell‐based assays leverage these features to create better in vitro prediction of complex biochemical responses in humans, with a focus on the evaluation of drug toxicity and efficacy prior to use in human clinical trials.

Funding History

April 2012$908K
October 2013$165K
May 2014$385K
November 2014$180K
December 2014$750K
December 2015$2.9M
December 2017$2.2M
May 2019$3.0M
April 2021$2.5M
December 2022$18.0M

Management

Co-founder & CEO

Matthew R. Gevaert

Chief Operations Officer

Lillia Holmes

President

Eric Perreault

Chief Commercial Officer

Stacy A. Chick

Board Member

Jason Robart

Vice President, Preclinical Services

Tessa DesRochers

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo